Psyence Biomedical Ltd.
PBM
$0.73
-$0.03-3.46%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.15M | 872.80K | 825.40K | 825.40K | 890.50K |
| Depreciation & Amortization | 1.30K | 1.30K | 1.20K | 1.20K | 1.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.51M | 1.21M | 864.90K | 864.90K | 1.16M |
| Operating Income | -1.51M | -1.21M | -864.90K | -864.90K | -1.16M |
| Income Before Tax | -753.30K | -996.40K | -974.40K | -974.40K | 141.50K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -753.30K | -996.40K | -974.40K | -974.40K | 141.50K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -753.30K | -996.40K | -974.40K | -974.40K | 141.50K |
| EBIT | -1.51M | -1.21M | -864.90K | -864.90K | -1.16M |
| EBITDA | -1.51M | -1.21M | -863.70K | -863.70K | -1.16M |
| EPS Basic | -3.18 | -5.88 | -17.05 | -17.05 | -- |
| Normalized Basic EPS | -3.94 | -4.46 | -8.74 | -8.74 | -- |
| EPS Diluted | -3.19 | -5.88 | -17.05 | -17.05 | -- |
| Normalized Diluted EPS | -3.94 | -4.46 | -8.74 | -8.74 | -- |
| Average Basic Shares Outstanding | 237.00K | 169.50K | 57.10K | 57.10K | -- |
| Average Diluted Shares Outstanding | 237.00K | 169.50K | 57.10K | 57.10K | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |